Bruce Keyt
2020
In 2020, Bruce Keyt earned a total compensation of $2.8M as Chief Scientific Officer at IGM Biosciences, a 359% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $223,128 |
|---|---|
| Option Awards | $2,125,995 |
| Salary | $413,200 |
| Total | $2,762,323 |
Keyt received $2.1M in option awards, accounting for 77% of the total pay in 2020.
Keyt also received $223.1K in non-equity incentive plan and $413.2K in salary.
Rankings
In 2020, Bruce Keyt's compensation ranked 4,179th out of 13,090 executives tracked by ExecPay. In other words, Keyt earned more than 68.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,179 out of 13,090 | 68th |
Division Manufacturing | 1,685 out of 5,624 | 70th |
Major group Chemicals And Allied Products | 646 out of 2,257 | 71st |
Industry group Drugs | 552 out of 1,957 | 72nd |
Industry Pharmaceutical Preparations | 420 out of 1,462 | 71st |
Source: SEC filing on April 29, 2021.
Keyt's colleagues
We found two more compensation records of executives who worked with Bruce Keyt at IGM Biosciences in 2020.
News
IGM Biosciences CEO Fred Schwarzer's 2022 pay falls 46% to $5.3M
April 27, 2023
IGM Biosciences CEO Fred Schwarzer's 2021 pay jumps 94% to $9.9M
April 27, 2022
IGM Biosciences CEO Fred Schwarzer's 2020 pay jumps 574% to $5.1M
April 29, 2021
IGM Biosciences CEO Fred Schwarzer's 2019 pay jumps 46% to $757K
April 21, 2020